FDA approval of IMULDOSA was granted based on a comprehensive clinical development program. The data showed that IMULDOSA is similar to its reference product STELARA in terms of pharmacokinetic ...

Individuals with self-reported moderate to severe psoriatic arthritis (PsA) face a higher disease burden, particularly among ...

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

Fatigue is a common problem for people with psoriatic arthritis. According to the National Psoriasis Foundation, some studies indicate that half of all psoriatic arthritis patients have ...

Arthritis, often thought to be an ailment of the elderly, is an autoimmune disease prevalent across all ages, particularly in ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

“The heroes here tonight are not make-believe heroes from Marvel Comics, but real-life heroes who have made an impact on ...

The following is a summary of “Opioid Use and Healthcare Utilization in Adults With Psoriatic Arthritis and Ankylosing ...

The following is a summary of “Difficult-to-Treat Concept in Psoriatic Arthritis: Analysis of 2 Potential Definitions in a ...

By Melanie Miller Dear Neighbor, I am the mother of a 33-year-old young man who has multiple health concerns which he did not bring upon himself. My son has Marfan Syndrome, epilepsy, psoriatic ...

Essentially, he was asking what makes RA different from the type of arthritis that you usually hear about: osteoarthritis.